Elaine J. Heron
Elaine J. Heron's purchase track record
Elaine J. Heron has only 1 open-market purchase with a full 6 months of price history after it -- too few to call a track record yet.
| Purchase | Stock | Amount | 3 months | 6 months | S&P 500, 6 mo. |
|---|---|---|---|---|---|
| 2/27/2026 | PVLA | $300K | -12.3% | +11.1% | +12.1% |
Computed by MarketWall from SEC Form 4 filings and daily closing prices (close on the purchase date to the close about 3 and 6 months later). Companies that have since delisted are not included. Past results, not investment advice.
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 4, 2026
BioMarin Reports Phase 3 Pompe Data, Expands AI Partnership. BioMarin presented phase‑3 results for its Pompe disease therapy POMBILITI® combined with OPFOLDA® at the World Muscle Society Congress, reporting sustained efficacy and no new safety signals. The company also announced a partnership with Profluent to use AI for designing enzyme therapies, and a license agreement with Ascendis Pharma that includes royalties on future sales. These developments highlight BioMarin’s focus on expanding its therapeutic pipeline and leveraging technology partnerships.
Transaction History
| PVLA | ▲ Buy | Open Market | 2,400 | $300K | 2/27/2026 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 5,047 | $318K | 6/3/2024 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 4,168 | $318K | 6/3/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,720 | $0 | 5/21/2024 | View on chart |
| BMRN | ▲ Buy | Grant | 4,190 | $0 | 5/23/2023 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 8,500 | $576K | 5/12/2023 | View on chart |
| BMRN | ▼ Sell | Tax Withholding | 6,137 | $576K | 5/12/2023 | View on chart |
| BMRN | ▲ Buy | Grant | 4,980 | $0 | 5/24/2022 | View on chart |
| BMRN | ▲ Buy | Option Exercise | 8,500 | $318K | 2/25/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 13, 2026
Palvella Therapeutics Shares New Data at Dermatology Conference
Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.
Palvella Therapeutics Shares New Data at Dermatology Conference. Palvella Therapeutics presented three posters at the Fall Clinical Dermatology 2026 conference, sharing new data on microcystic lymphatic malformations and DSAP. This update highlights ongoing research in the company's key therapeutic areas. Meanwhile, HC Wainwright lowered its price target to $246 while maintaining its stance on the stock.